Adverse effects of treatment in childhood acute lymphoblastic leukemia: General overview and implications for long-term cardiac health

Expert Review of Hematology

Volumn 4, Issue 2, 2011, Pages 185-197

  Ness, Kirsten K ^a   Armenian, Saro H ^b   Kadan Lottick, Nina ^c   Gurney, James G ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute lymphoblastic leukemia; cardiac; epidemiology; healthy lifestyle; insulin resistance; late effects; obesity; pediatric; survivorship

Indexed keywords

ANTHRACYCLINE; ASPARAGINASE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; GLUCOCORTICOID; MERCAPTOPURINE; METHOTREXATE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; BODY EQUILIBRIUM; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHILDHOOD LEUKEMIA; COGNITIVE DEFECT; DISEASE ASSOCIATION; DISEASE SEVERITY; FITNESS; GROWTH HORMONE DEFICIENCY; HUMAN; INSULIN RESISTANCE; MORBIDITY; MUSCLE WEAKNESS; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTIBIOTICS, ANTINEOPLASTIC; CHILD; HEART DISEASES; HUMAN GROWTH HORMONE; HUMANS; METABOLIC DISEASES; OBESITY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; STEM CELL TRANSPLANTATION;

EID: 79955054335     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.11.8     Document Type: Review

References (159)

1. Scheurer ME, Bondy ML, Gurney JG. Epidemiology of childhood cancer. In:Principles and Practice of Pediatric Oncology. Pizzo PA, Poplack DG (Eds).Lippincott Williams & Wilkins, PA, USA, 2-16 (2011).
2. Pui CH, Campana D, Pei D et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N. Engl. J. Med. 360(26), 2730-2741 (2009).
3. Shah A, Stiller CA, Kenward MG, Vincent T, Eden TO, Coleman MP. Childhood leukaemia: long-term excess mortality and the proportion 'cured'. Br. J. Cancer 99(1), 219-223 (2008). (Pubitemid 351920248)
4. Skinner R, Wallace WH, Levitt GA. Long-term follow-up of people who have survived cancer during childhood. Lancet Oncol. 7(6), 489-498 (2006). (Pubitemid 44207842)
5. Mariotto AB, Rowland JH, Yabroff KR et al. Long-term survivors of childhood cancers in the United States. Cancer Epidemiol. Biomarkers Prev. 18(4), 1033-1040 (2009).
6. Robison LL, Bhatia S. Late-effects among survivors of leukaemia and lymphoma during childhood and adolescence. Br. J. Haematol. 122(3), 345-359 (2003). (Pubitemid 36951619)
7. Oeffinger KC, Mertens AC, Sklar CA et al. Chronic health conditions in adult survivors of childhood cancer. N. Engl. J. Med. 355(15), 1572-1582 (2006). (Pubitemid 44547808)
8. Margolin JF, Rabin KR, Steuber CP, Poplack DG. Acute lymphoblastic leukemia. In:Principles and Practice of Pediatric Oncology. Pizzo PA, Poplack DG (Eds).Lippincott Williams & Wilkins, PA, USA, 518-565 (2011).
9. Pui C-H, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 371(9617), 1030-1043 (2008). (Pubitemid 351389536)
10. Neglia JP, Friedman DL, Yasui Y et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J. Natl Cancer Inst. 93(8), 618-629 (2001). (Pubitemid 32409629)
11. Feig SA. Second malignant neoplasms after successful treatment of childhood cancers. Blood Cells Mol. Dis. 27(3), 662-666 (2001). (Pubitemid 32757062)
12. Mertens AC, Yasui Y, Neglia JP et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J. Clin. Oncol. 19(13), 3163-3172 (2001). (Pubitemid 32591432)
13. Moller TR, Garwicz S, Barlow L et al. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J. Clin. Oncol. 19(13), 3173-3181 (2001). (Pubitemid 32591433)
14. Armstrong GT, Liu Q, Yasui Y et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J. Clin. Oncol. 27(14), 2328-2338 (2009).
15. Lipschultz SE. Exposure to anthracyclines during childhood causes cardiac injury. Sem. Oncol. 33, 8-14 (2006).
16. Kremer LC, Caron HN. Anthracycline cardiotoxicity in children. N. Engl. J. Med. 351(2), 120-121 (2004). (Pubitemid 38886645)
17. Mulrooney DA, Yeazel MW, Kawashima T et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339, b4606 (2009).
18. Esbenshade AJ, Simmons JH, Koyama T, Koehler E, Whitlock JA, Friedman DL. Body mass index and blood pressure changes over the course of treatment of pediatric acute lymphoblastic leukemia. Pediatr. Blood Cancer 56(3), 372-378 (2011).
19. Cohen LE. Endocrine late effects of cancer treatment. Curr. Opin. Pediatr. 15(1), 3-9 (2003). (Pubitemid 36132610)
20. Diamond FB Jr, Bercu BB. Endocrine sequelae of cancer therapy in childhood. J. Endocrinol. Invest. 24(9), 648-658 (2001). (Pubitemid 32982335)
21. Dieckmann K, Widder J, Potter R. Long-term side effects of radiotherapy in survivors of childhood cancer. Front Radiat. Ther. Oncol. 37, 57-68 (2002).
22. Oberfield SE, Sklar CA. Endocrine sequelae in survivors of childhood cancer. Adolesc. Med. 13(1), 161-169, viii (2002).
23. Hovi L, Era P, Rautonen J, Siimes MA. Impaired muscle strength in female adolescents and young adults surviving leukemia in childhood. Cancer 72(1), 276-281 (1993). (Pubitemid 23182085)
24. Murphy AJ, Wells JC, Williams JE, Fewtrell MS, Davies PS, Webb DK. Body composition in children in remission from acute lymphoblastic leukemia. Am. J. Clin. Nutr. 83(1), 70-74 (2006). (Pubitemid 44699237)
25. Ness KK, Mertens AC, Hudson MM et al. Limitations on physical performance and daily activities among long-term survivors of childhood cancer. Ann. Intern. Med. 143(9), 639-647 (2005).
26. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J. Neurol. 249(1), 9-17 (2002). (Pubitemid 34119018)
27. Cole PD, Karmen BA. Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia. Men. Retard. Dev. Disabil. Res. Rev. 12(3), 174-183 (2006). (Pubitemid 44646326)
28. Kadan-Lottick NS, Ness KK, Bhatia S, Gurney JG. Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. JAMA 290(15), 2008-2014 (2003). (Pubitemid 37430583)
29. Moller TR, Garwicz S, Barlow L et al. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J. Clin. Oncol. 19(13), 3173-3181 (2001). (Pubitemid 32591433)
30. Ness KK, Leisenring W, Goodman P et al. Assessment of selection bias in clinic-based populations of childhood cancer survivors: a report from the childhood cancer survivor study. Pediatr. Blood Cancer 52(3), 379-386 (2009).
31. Mertens AC, Walls RS, Taylor L et al. Characteristics of childhood cancer survivors predicted their successful tracing. J. Clin. Epidemiol. 57(9), 933-944 (2004). (Pubitemid 39422530)
32. Robison LL, Armstrong GT, Boice JD et al. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J. Clin. Oncol. 27(14), 2308-2318 (2009).
33. Robison LL, Mertens AC, Boice JD et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med. Pediatr. Oncol. 38(4), 229-239 (2002). (Pubitemid 34258414)
34. Hawkins MM, Lancashire ER, Winter DL et al. The British Childhood Cancer Survivor Study: objectives, methods, population structure, response rates and initial descriptive information. Pediatr. Blood Cancer 50(5), 1018-1025 (2008). (Pubitemid 351500181)
35. Taylor A, Dal Grande E, Gill T et al. Comparing self-reported and measured high blood pressure and high cholesterol status using data from a large representative cohort study. Aust. NZ J. Public Health 34(4), 394-400 (2010).
36. Reulen RC, Winter DL, Frobisher C et al. Long-term cause-specific mortality among survivors of childhood cancer. JAMA 304(2), 172-179 (2010).
37. Yeh JM, Nekhlyudov L, Goldie SJ, Mertens AC, Diller L. A model-based estimate of cumulative excess mortality in survivors of childhood cancer. Ann. Intern. Med. 152(7), 409-417, W131-W408 (2010).
38. Printz C. Adult survivors of childhood and adolescent cancer have more heart disease. Cancer 116(11), 2507 (2010).
39. Meacham LR, Chow EJ, Ness KK et al. Cardiovascular risk factors in adult survivors of pediatric cancer - a report from the childhood cancer survivor study. Cancer Epidemiol. Biomarkers Prev. 19(1), 170-181 (2010).
40. Levitt G, Anazodo A, Burch M, Bunch K. Cardiac or cardiopulmonary transplantation in childhood cancer survivors: an increasing need? Eur. J. Cancer 45(17), 3027-3034 (2009).
41. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 94(4), 525-533 (2008). (Pubitemid 351441417)
42. Adams MJ, Lipshultz SE. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr. Blood Cancer 44(7), 600-606 (2005). (Pubitemid 40629208)
43. Berry GJ, Jorden M. Pathology of radiation and anthracycline cardiotoxicity. Pediatr. Blood Cancer 44, 630-637 (2005). (Pubitemid 40629213)
44. Adams MJ, Hardenbergh PH, Constine LS, Lipshultz SE. Radiation-associated cardiovascular disease. Crit. Rev. Oncol. Hematol. 45, 55-75 (2003). (Pubitemid 35449788)
45. Kremer LCM, Van Dalen EC, Offringa M, Otenkamp J, Voute PA. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J. Clin. Oncol. 19, 191-196 (2001). (Pubitemid 32063496)
46. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin. Oncol. 25, 72-85 (1998). (Pubitemid 28460388)
47. Kremer LC, Van Dalen EC, Offringa M, Voute PA. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann. Oncol. 13(4), 503-512 (2002). (Pubitemid 34461132)
48. Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE. Anthracycline-induced cardiotoxicity in children and young adults. Crit. Rev. Oncol. Hematol. 27(1), 53-68 (1998). (Pubitemid 28275509)
49. Lipshultz SE, Lipshultz SR, Mone SM, Al E. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N. Engl. J. Med. 332, 1738-1743 (1995).
50. Pein F, Sakiroglu O, Dahan M et al. Cardiac abnormalities 15 years after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br. J. Cancer 91, 37-44 (2004). (Pubitemid 39013042)
51. Felker GM, Thompson RE, Hare JM et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N. Engl. J. Med. 342(15), 1077-1084 (2000). (Pubitemid 30207690)
52. Smibert E, Carlin JB, Vidmar S, Wilkinson LC, Newton M, Weintraub RG. Exercise echocardiography reflects cumulative anthracycline exposure during childhood. Pediatr. Blood Cancer 42(7), 556-562 (2004). (Pubitemid 38669742)
53. Hudson MM, Rai SN, Nunez C et al. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J. Clin. Oncol. 25(24), 3635-3643 (2007). (Pubitemid 47372601)
54. Rathe M, Carlsen NL, Oxhoj H, Nielsen G. Long-term cardiac follow-up of children treated with anthracycline doses of 300 mg/m2 or less for acute lymphoblastic leukemia. Pediatr. Blood Cancer 54(3), 444-448 (2010).
55. Deng S, Wojnowski L. Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovasc. Toxicol. 7(2), 129-134 (2007). (Pubitemid 47339859)
56. Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 112(12), 2789-2795 (2008). (Pubitemid 351969225)
57. Blanco JG, Sun CL, Landier W et al. Anthracycline-related cardiomyopathy in childhood cancer survivors and association with polymorphisms in the carbonyl reductase genes: a Children's Oncology Group study. J. Clin. Oncol. 28(Suppl. 15), a9512 (2010).
58. Poutanen T, Ikonen A, Jokinen E, Vainio P, Tikanoja T. Transthoracic three-dimensional echocardiography is as good as magnetic resonance imaging in measuring dynamic changes in left ventricular volume during the heart cycle in children. Eur. J. Echocardiogr. 2(1), 31-39 (2001). (Pubitemid 32496440)
59. Poutanen T, Tikanoja T, Riikonen P, Silvast A, Perkkio M. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J. Clin. Oncol. 21(12), 2349-2356 (2003). (Pubitemid 46621873)
60. Shankar SM, Marina N, Hudson MM et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics 121(2), e387-e396 (2008). (Pubitemid 351198462)
61. Zee P, Chen CH. Prevalence of obesity in children after therapy for acute lymphoblastic leukemia. Am. J. Pediatr. Hematol. Oncol. 8(4), 294-299 (1986). (Pubitemid 17229761)
62. Reilly JJ, Ventham JC, Newell J, Aitchison T, Wallace WH, Gibson BE. Risk factors for excess weight gain in children treated for acute lymphoblastic leukaemia. Int. J. Obes. Relat. Metab. Disord. 24(11), 1537-1541 (2000).
63. Oeffinger KC, Mertens AC, Sklar CA et al. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J. Clin. Oncol. 21(7), 1359-1365 (2003). (Pubitemid 46606416)
64. Withycombe JS, Post-White JE, Meza JL et al. Weight patterns in children with higher risk ALL: a report from the Children's Oncology Group (COG) for CCG 1961. Pediatr. Blood Cancer 53(7), 1249-1254 (2009).
65. Rogers PC, Meacham LR, Oeffinger KC, Henry DW, Lange BJ. Obesity in pediatric oncology. Pediatr. Blood Cancer 45(7), 881-891 (2005). (Pubitemid 41552155)
66. Skoczen S, Surmiak M, Strojny W. Survivors of acute lymphoblastic leukemia and body mass changes. Expert Opin. Drug Saf. 9(1), 65-77 (2010).
67. Skolin I, Hursti UK, Wahlin YB. Parents' perception of their child's food intake after the start of chemotherapy. J. Pediatr. Oncol. Nurs. 18(3), 124-136 (2001). (Pubitemid 33602011)
68. Reilly JJ, Ventham JC, Ralston JM, Donaldson M, Gibson B. Reduced energy expenditure in preobese children treated for acute lymphoblastic leukemia. Pediatr. Res. 44(4), 557-562 (1998). (Pubitemid 28447343)
69. Jansen H, Postma A, Stolk RP, Kamps WA. Acute lymphoblastic leukemia and obesity: increased energy intake or decreased physical activity? Support Care Cancer 17(1), 103-106 (2009).
70. Gurney JG, Kadan-Lottick NS, Packer RJ et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer 97(3), 663-673 (2003). (Pubitemid 36125844)
71. Abayomi OK, Sadeghi-Nejad A. The incidence of late endocrine dysfunction following irradiation for childhood medulloblastoma. Int. J. Radiat. Oncol. Biol. Phys. 12(6), 945-948 (1986). (Pubitemid 16057580)
72. Taskinen M, Lipsanen-Nyman M, Tiitinen A, Hovi L, Saarinen-Pihkala UM. Insufficient growth hormone secretion is associated with metabolic syndrome after allogeneic stem cell transplantation in childhood. J. Pediatr. Hematol. Oncol. 29(8), 529-534 (2007). (Pubitemid 47356806)
73. Gurney JG, Ness KK, Sibley SD et al. Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. Cancer 107(6), 1303-1312 (2006). (Pubitemid 44452780)
74. Link K, Moell C, Garwicz S et al. Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood. J. Clin. Endocrinol. Metab. 89(10), 5003-5012 (2004). (Pubitemid 39391441)
75. Brennan BM, Rahim A, Blum WF, Adams JA, Eden OB, Shalet SM. Hyperleptinaemia in young adults following cranial irradiation in childhood: growth hormone deficiency or leptin insensitivity? Clin. Endocrinol. (Oxf.) 50(2), 163-169 (1999). (Pubitemid 29100001)
76. Jarfelt M, Lannering B, Bosaeus I, Johannsson G, Bjarnason R. Body composition in young adult survivors of childhood acute lymphoblastic leukaemia. Eur. J. Endocrinol. 153(1), 81-89 (2005). (Pubitemid 41030519)
77. Talvensaari KK, Lanning M, Tapanainen P, Knip M. Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J. Clin. Endocrinol. Metab. 81(8), 3051-3055 (1996). (Pubitemid 26323907)
78. Ascaso JF, Romero P, Real JT et al. Abdominal obesity, insulin resistance, and metabolic syndrome in a southernEuropean population. Eur. J. Intern. Med. 14(2), 101-106 (2003). (Pubitemid 36457952)
79. Lee JM, Davis MM, Woolford SJ, Gurney JG. Waist circumference percentile thresholds for identifying adolescents with insulin resistance in clinical practice. Pediatr. Diabetes 10(5), 336-342 (2009).
80. Wahrenberg H, Hertel K, Leijonhufvud BM, Persson LG, Toft E, Arner P. Use of waist circumference to predict insulin resistance: retrospective study. BMJ 330(7504), 1363-1364 (2005). (Pubitemid 40839563)
81. Siviero-Miachon AA, Spinola-Castro AM, Guerra-Junior G. Detection of metabolic syndrome features among childhood cancer survivors: a target to prevent disease. Vasc. Health Risk Manag. 4(4), 825-836 (2008).
82. Wong ND. Metabolic syndrome: cardiovascular risk assessment and management. Am. J. Cardiovasc. Drugs 7(4), 259-272 (2007). (Pubitemid 47295836)
83. Lowas S, Malempati S, Marks D. Body mass index predicts insulin resistance in survivors of pediatric acute lymphoblastic leukemia. Pediatr. Blood Cancer 53(1), 58-63 (2009).
84. Talvensaari KK, Jamsen A, Vanharanta H, Lanning M. Decreased isokinetic trunk muscle strength and performance in long-term survivors of childhood malignancies: correlation with hormonal defects. Arch. Phys. Med. Rehabil. 76(11), 983-988 (1995).
85. Oeffinger KC, Adams-Huet B, Victor RG et al. Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia. J. Clin. Oncol. 27(22), 3698-3704 (2009).
86. van Dalen EC, van Der Pal HJ, van Den Bos C, Kok WE, Caron HN, Kremer LC. Clinical heart failure during pregnancy and delivery in a cohort of female childhood cancer survivors treated with anthracyclines. Eur. J. Cancer 42(15), 2549-2553 (2006). (Pubitemid 44468382)
87. Baker KS, Ness KK, Steinberger J et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood 109(4), 1765-1772 (2007). (Pubitemid 46239613)
88. Ness KK, Baker KS, Dengel DR et al. Body composition, muscle strength deficits and mobility limitations in adult survivors of childhood acute lymphoblastic leukemia. Pediatr. Blood Cancer 49(7), 975-981 (2007). (Pubitemid 350022455)
89. Gocha Marchese V, Chiarello LA, Lange BJ. Strength and functional mobility in children with acute lymphoblastic leukemia. Med. Pediatr. Oncol. 40(4), 230-232 (2003). (Pubitemid 36222828)
90. Wright MJ, Halton JM, Martin RF, Barr RD. Long-term gross motor performance following treatment for acute lymphoblastic leukemia. Med. Pediatr. Oncol. 31(2), 86-90 (1998). (Pubitemid 28341021)
91. Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br. J. Haematol. 129(6), 734-745 (2005). (Pubitemid 40904523)
92. Waber DP, Carpentieri SC, Klar N et al. Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. J. Pediatr. Hematol. Oncol. 22(3), 206-213 (2000). (Pubitemid 32268304)
93. Gomber S, Dewan P, Chhonker D. Vincristine induced neurotoxicity in cancer patients. Indian J. Pediatr. 77(1), 97-100 (2010).
94. Reinders-Messelink HA, Van Weerden TW, Fock JM et al. Mild axonal neuropathy of children during treatment for acute lymphoblastic leukaemia. Eur. J. Paediatr. Neurol. 4(5), 225-233 (2000).
95. Legha SS. Vincristine neurotoxicity. Pathophysiology and management. Med. Toxicol. 1(6), 421-427 (1986).
96. Harila-Saari AH, Huuskonen UE, Tolonen U, Vainionpaa LK, Lanning BM. Motor nervous pathway function is impaired after treatment of childhood acute lymphoblastic leukemia: a study with motor evoked potentials. Med. Pediatr. Oncol. 36(3), 345-351 (2001). (Pubitemid 32198509)
97. Wright MJ, Halton JM, Barr RD. Limitation of ankle range of motion in survivors of acute lymphoblastic leukemia: a cross-sectional study. Med. Pediatr. Oncol. 32(4), 279-282 (1999). (Pubitemid 29147102)
98. Ramchandren S, Leonard M, Mody RJ et al. Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J. Peripher. Nerv. Syst. 14(3), 184-189 (2009).
99. Harila-Saari AH, Vainionpaa LK, Kovala TT, Tolonen EU, Lanning BM. Nerve lesions after therapy for childhood acute lymphoblastic leukemia. Cancer 82(1), 200-207 (1998). (Pubitemid 28070498)
100. Peltier AC, Russell JW. Recent advances in drug-induced neuropathies. Curr. Opin. Neurol. 15(5), 633-638 (2002). (Pubitemid 35176699)
101. Topp KS, Tanner KD, Levine JD. Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J. Comp. Neurol. 424(4), 563-576 (2000). (Pubitemid 30643051)
102. Mercuri E, Poulton J, Buck J et al. Vincristine treatment revealing asymptomatic hereditary motor sensory neuropathy type 1A. Arch. Dis. Child. 81(5), 442-443 (1999). (Pubitemid 29501382)
103. Bermudez M, Fuster JL, Llinares E, Galera A, Gonzalez C. Itraconazole-related increased vincristine neurotoxicity: case report and review of literature. J. Pediatr. Hematol. Oncol. 27(7), 389-392 (2005). (Pubitemid 41077029)
104. Bohme A, Ganser A, Hoelzer D. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann. Hematol. 71(6), 311-312 (1995). (Pubitemid 26002070)
105. Mantadakis E, Amoiridis G, Kondi A, Kalmanti M. Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia. J. Pediatr. Hematol. Oncol. 29(2), 130 (2007). (Pubitemid 46213863)
106. Crom WR, De Graaf SS, Synold T et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J. Pediatr. 125(4), 642-649 (1994). (Pubitemid 24318444)
107. Dambska M, Muzylak M, Maslinska D. The features of peripheral nerve lesions in young and adult rabbits after vincristine administration. Folia Neuropathol. 33(1), 21-24 (1995).
108. Reinders-Messelink H, Schoemaker M, Snijders T et al. Motor performance of children during treatment for acute lymphoblastic leukemia. Med. Pediatr. Oncol. 33(6), 545-550 (1999).
109. Galea V, Wright MJ, Barr RD. Measurement of balance in survivors of acute lymphoblastic leukemia in childhood. Gait Posture 19(1), 1-10 (2004). (Pubitemid 38096405)
110. Wright MJ, Galea V, Barr RD. Proficiency of balance in children and youth who have had acute lymphoblastic leukemia. Phys. Ther. 85(8), 782-790 (2005). (Pubitemid 41060369)
111. Hartman A, van den Bos C, Stijnen T, Pieters R. Decrease in motor performance in children with cancer is independent of the cumulative dose of vincristine. Cancer 106(6), 1395-1401 (2006). (Pubitemid 43363920)
112. Moorkens G, Berwaerts J, Wynants H, Abs R. Characterization of pituitary function with emphasis on GH secretion inthe chronic fatigue syndrome. Clin. Endocrinol. 53(1), 99-106 (2000). (Pubitemid 30646132)
113. Weyer C, Bogardus C, Pratley RE. Metabolic factors contributing to increased resting metabolic rate and decreased insulin-induced thermogenesis during the development of Type 2 diabetes. Diabetes 48(8), 1607-1614 (1999). (Pubitemid 29356870)
114. Warner JT, Bell W, Webb DK, Gregory JW. Relationship between cardiopulmonary response to exercise and adiposity in survivors of childhood malignancy. Arch. Dis. Child. 76(4), 298-303 (1997). (Pubitemid 27174537)
115. De Caro E, Fioredda F, Calevo MG et al. Exercise capacity in apparently healthy survivors of cancer. Arch. Dis. Child. 91(1), 47-51 (2006). (Pubitemid 43059173)
116. Van Brussel M, Takken T, Lucia A, van der Net J, Helders PJ. Is physical fitness decreased in survivors of childhood leukemia? A systematic review. Leukemia 19(1), 13-17 (2005). (Pubitemid 40090069)
117. American College of Sports Medicine. ACSM's Guidelines for Exercise Testing and Prescription. Lippincott Williams & Wilkins, Baltimore, MA, USA (2000).
118. Kadan-Lottick NS, Zeltzer LK, Liu Q et al. Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers. J. Natl Cancer Inst. 102(12), 881-893 (2010).
119. Copeland DR, Fletcher JM, Pfefferbaum-Levine B, Jaffe N, Ried H, Maor M. Neuropsychological sequelae of childhood cancer in long-term survivors. Pediatrics 75(4), 745-753 (1985). (Pubitemid 15079531)
120. Halberg FE, Kramer JH, Moore IM, Wara WM, Matthay KK, Ablin AR. Prophylactic cranial irradiation dose effects on late cognitive function in children treated for acute lymphoblastic leukemia. Int. J. Radiat. Oncol. Biol. Phys. 22(1), 13-16 (1992).
121. Jankovic M, Brouwers P, Valsecchi MG et al. Association of 1800 cGy cranial irradiation with intellectual function in children with acute lymphoblastic leukaemia. ISPACC. International Study Group on Psychosocial Aspects of Childhood Cancer. Lancet 344(8917), 224-227 (1994). (Pubitemid 24229009)
122. Langer T, Martus P, Ottensmeier H, Hertzberg H, Beck JD, Meier W. CNS late-effects after ALL therapy in childhood. Part III: neuropsychological performance in long-term survivors of childhood ALL: impairments of concentration, attention, and memory. Med. Pediatr. Oncol. 38(5), 320-328 (2002). (Pubitemid 34493111)
123. Kingma A, Rammeloo LA, van Der Does-van den Berg A, Rekers-Mombarg L, Postma A. Academic career after treatment for acute lymphoblastic leukaemia. Arch. Dis. Child. 82(5), 353-357 (2000). (Pubitemid 30307760)
124. Riccardi R, Brouwers P, Di Chiro G, Poplack DG. Abnormal computed tomography brain scans in children with acute lymphoblastic leukemia: serial long-term follow-up. J. Clin. Oncol. 3(1), 12-18 (1985). (Pubitemid 15187693)
125. Crosley CJ, Rorke LB, Evans A, Nigro M. Central nervous system lesions in childhood leukemia. Neurology 28(7), 678-685 (1978). (Pubitemid 8364273)
126. Price R. Therapy related central nervous system diseases in children with acute lymphocytic leukemia. In:Central Nervous System Lukemia: Prevention and Treatment. Mastrangelo R, Poplack D, Riccardi R (Eds).Martinus Nijhoff Publishers, Boston, MA, USA, 71-83 (1983).
127. Reddick WE, Shan ZY, Glass JO et al. Smaller white-matter volumes are associated with larger deficits in attention and learning among long-term survivors of acute lymphoblastic leukemia. Cancer 106(4), 941-949 (2006). (Pubitemid 43238463)
128. Meadows AT, Gordon J, Massari DJ, Littman P, Fergusson J, Moss K. Declines in IQ scores and cognitive dysfunctions in children with acute lymphocytic leukaemia treated with cranial irradiation. Lancet 2(8254), 1015-1018 (1981). (Pubitemid 11027578)
129. Cousens P, Waters B, Said J, Stevens M. Cognitive effects of cranial irradiation in leukaemia: a survey and meta-analysis. J. Child Psychol. Psychiatry 29(6), 839-852 (1988).
130. Rogers J, Britton PG, Morris RG, Kernahan J, Craft A. Memory after treatment for acute lymphoblastic leukemia. Arch. Dis. Child. 67, 266-268 (1992).
131. Ochs J, Mulhern R, Fairclough D et al. Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: a prospective study. J. Clin. Oncol. 9(1), 145-151 (1991).
132. Brown RT, Madan-Swain A. Cognitive, neuropsychological, and academic sequelae in children with leukemia. J. Learn. Disabil. 26(2), 74-90 (1993).
133. Stehbens JA, Kaleita TA, Noll RB et al. CNS prophylaxis of childhood leukemia: what are the long-term neurological, neuropsychological, and behavioral effects? Neuropsychol. Rev. 2(2), 147-177 (1991).
134. Waber DP, Urion DK, Tarbell NJ, Niemeyer C, Gelber R, Sallan SE. Late effects of central nervous system treatment of acute lymphoblastic leukemia in childhood are sex-dependent. Dev. Med. Child Neurol. 32(3), 238-248 (1990). (Pubitemid 20069553)
135. Laningham FH, Kun LE, Reddick WE, Ogg RJ, Morris EB, Pui CH. Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae. Neuroradiology 49(11), 873-888 (2007). (Pubitemid 350104848)
136. Kerr JZ, Berg S, Blaney SM. Intrathecal chemotherapy. Crit. Rev. Oncol. Hematol. 37(3), 227-236 (2001). (Pubitemid 32193008)
137. Mahoney DHJ, Shuster JJ, Nitschke R et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy - a Pediatric Oncology Group study. J. Clin. Oncol. 16(5), 1712-1722 (1998).
138. Krull KR, Brouwers P, Jain N et al. Folate pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivors. J. Pediatr. 152(1), 101-105 (2008). (Pubitemid 350265921)
139. Anderson FS, Kunin-Batson AS. Neurocognitive late effects of chemotherapy in children: the past 10 years of research on brain structure and function. Pediatr. Blood Cancer 52(2), 159-164 (2009).
140. Bender BG, Lerner JA, Poland JE. Association between corticosteroids and psychologic change in hospitalized asthmatic children. Ann. Allergy 66(5), 414-419 (1991).
141. Yeh TF, Lin YJ, Lin HC et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N. Engl. J. Med. 350(13), 1304-1313 (2004). (Pubitemid 38375365)
142. Young AH, Sahakian BJ, Robbins TW, Cowen PJ. The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers. Psychopharmacology (Berl.) 145(3), 260-266 (1999). (Pubitemid 29393475)
143. Danilczuk Z, Ossowska G, Lupina T, Cieslik K, Zebrowska-Lupina I. Effect of NMDA receptor antagonists on behavioral impairment induced by chronic treatment with dexamethasone. Pharmacol. Rep. 57(1), 47-54 (2005). (Pubitemid 40601540)
144. Kadan-Lottick NS, Brouwers P, Breiger D et al. A comparison of neurocognitive functioning in children previously randomized to dexamethasone orprednisone in the treatment of childhood acute lymphoblastic leukemia. Blood 114(9), 1746-1752 (2009).
145. Buizer AI, De Sonneville LM, Van Den Heuvel-Eibrink MM, Veerman AJ. Chemotherapy and attentional dysfunction in survivors of childhood acute lymphoblastic leukemia: effect of treatment intensity. Pediatr. Blood Cancer 45(3), 281-290 (2005). (Pubitemid 41077161)
146. Jansen NC, Kingma A, Schuitema A, Bouma A, Veerman AJ, Kamps WA. Neuropsychological outcome in chemotherapy-only-treated children with acute lymphoblastic leukemia. J. Clin. Oncol. 26(18), 3025-3030 (2008).
147. Gurney JG, Donohue JE, Ness KK, O'Leary M, Glasser SP, Baker KS. Health knowledge about symptoms of heart attack and stroke in adult survivors of childhood acute lymphoblastic leukemia. Ann. Epidemiol. 17(10), 778-781 (2007). (Pubitemid 47393638)
148. Kadan-Lottick NS, Robison LL, Gurney JG et al. Childhood cancer survivors' knowledge about their past diagnosis and treatment: Childhood Cancer Survivor Study. JAMA 287(14), 1832-1839 (2002). (Pubitemid 34303628)
149. Hensley ML, Hagerty KL, Kewalramani T et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J. Clin. Oncol. 27(1), 127-145 (2009).
150. Barry EV, Vrooman LM, Dahlberg SE et al. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J. Clin. Oncol. 26(7), 1106-1111 (2008).
151. Lipshultz SE, Colan SD. Cardiovascular trials in long-term survivors of childhood cancer. J. Clin. Oncol. 22(5), 769-773 (2004). (Pubitemid 41103586)
152. Silber JH, Cnaan A, Clark BJ et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J. Clin. Oncol. 22(5), 820-828 (2004). (Pubitemid 41103593)
153. Mayer EI, Reuter M, Dopfer RE, Ranke MB. Energy expenditure, energy intake and prevalence of obesity after therapy for acute lymphoblastic leukemia during childhood. Horm. Res. 53(4), 193-199 (2000).
154. Tercyak KP, Donze JR, Prahlad S, Mosher RB, Shad AT. Multiple behavioral risk factors among adolescent survivors of childhood cancer in the Survivor Health and Resilience Education (SHARE) program. Pediatr. Blood Cancer 47(6), 825-830 (2006). (Pubitemid 44476761)
155. Keats MR, Culos-Reed SN, Courneya KS, Mcbride M. Understanding physical activity in adolescent cancer survivors: an application of the theory of planned behavior. Psychooncology 16(5), 448-457 (2007). (Pubitemid 46840056)
156. Florin TA, Fryer GE, Miyoshi T et al. Physical inactivity in adult survivors of childhood acute lymphoblastic leukemia: a report from the childhood cancer survivor study. Cancer Epidemiol. Biomarkers Prev. 16(7), 1356-1363 (2007). (Pubitemid 47076864)
157. Hartman A, Te Winkel M, Van Beek R et al. A randomized trial investigating an exercise program to prevent reduction of bone mineral density and impairment of motor performance during treatment for childhood acute lymphoblastic leukemia. Pediatr. Blood Cancer 53(1), 64-71 (2009).
158. Wolin KY, Ruiz JR, Tuchman H, Lucia A. Exercise in adult and pediatric hematological cancer survivors: an intervention review. Leukemia 24(6), 1113-1120 (2010).
159. Robien K, Ness KK, Klesges LM, Baker KS, Gurney JG. Poor adherence to dietary guidelines among adult survivors of childhood acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 30(11), 815-822 (2008).